Interactions among drugs for HIV and opportunistic infections

New England Journal of Medicine

Volumn 344, Issue 13, 2001, Pages 984-996

  Piscitelli, Stephen C ^a,c   Gallicano, Keith D ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTACID AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; DIGOXIN; EFAVIRENZ; GANCICLOVIR; GLYCOPROTEIN P; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; NEVIRAPINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; FOOD DRUG INTERACTION; FRUIT JUICE; GRAPEFRUIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW;

ABSORPTION; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035967245     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103293441307     Document Type: Review

References (121)

1. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro
2. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: Report of two randomized trials (ACTG 290 and 298)
3. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation
4. Effect of sucralfate on absorption of norfloxacin and ofloxacin
5. Cations in the didanosine tablet reduce ciprofloxacin bioavailability
6. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
7. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus
8. Pharmacokinetic (PK) drug interaction with saquinavir soft gelatin capsule
9. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
10. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
11. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients
12. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole
13. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro
14. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
15. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature
16. Update: Clinically significant cytochrome P-450 drug interactions
17. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir
18. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
19. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
20. CYP3A gene expression in human gut epithelium
21. Drug interactions with grapefruit juice: Extent, probable mechanism and clinical relevance
22. Grapefruit juice-drug interactions
23. Expression of a multidrug-resistance gene in human tumors and tissues
24. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
25. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
26. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
27. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
28. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral delivery
29. Grapefruit juice (GJ) increases gastric pH, but does not affect indinavir (IDV) exposure, in HIV patients
30. Grapefruit juice activates P-glycoprotein-mediated drug transport
31. Inhibition of CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components
32. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
33. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
34. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
35. Effects of ranitidine and sucralfate on ketoconazole bioavailability
36. Influence of concomitant food intake on the oral absorption of two thiazole antifungal agents, intraconazole and fluconazole
37. Increased gastric pH and the bioavailability of fluconazole and ketoconazole
38. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans
39. Probenecid and zidovudine metabolism
40. The use of human hepatocyte cultures to study the induction of cytochrome P-450
41. In vitro effects of HIV protease inhibitors on methadone metabolism
42. Ritonavir does not increase methadone exposure in healthy volunteers
43. Cytochrome P450 2B6 (CYP2B6) metabolizes methadone (M) preferentially and stereospecifically: An explanation of drug interaction with antiretroviral drugs
44. The effect of ritonavir (RTV)/saquinavir (SQV) on the stereoselective pharmacokinetics (PK) of methadone (M)
45. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes
46. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin
47. Alprazolam-ritonavir interaction: Implications for product labeling
48. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: A concentration-dependent interaction
49. Drug interactions with d4T phosphorylation in vitro
50. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2- (phosphonylmethoxy)propyl]adenine against drug susceptible and drug-resistant human immunodeficiency virus isolates
51. Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients
52. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
53. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
54. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors
55. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
56. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals
57. Drug interaction study between saquinavir (SQV) and nevirapine (NVP)
58. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir
59. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients
60. Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): Preliminary safety, activity and pharmacokinetic (PK) interactions
61. Efavirenz: Shifting the paradigm in adult HIV-1 infection
62. Pharmacokinetics of efavirenz (EFV) and ritonavir (RIT) after multiple oral doses in healthy volunteers
63. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers
64. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
65. Nevirapine induced methadone withdrawal: Implications for antiretroviral treatment of opiate dependent HIV infected patients
66. Managing methadone and non-nucleoside reverse transcriptase inhibitors: Guidelines for clinical practice
67. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
68. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline
69. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers
70. Nelfinavir mesylate: A protease inhibitor
71. Ritonavir enables combined therapy with rifampin and saquinavir
72. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin
73. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin
74. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse effects
75. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors
76. Carbamazepine-indinavir interaction causes antiretroviral failure
77. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
78. Evaluation of the pharmacokinetic (PK) interaction between phenytoin (Phen) and nelfinavir (NFV) in healthy volunteers at steady state
79. Pharmacokinetic interaction between ritonavir and clarithromycin
80. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin
81. Azithromycin and terfenadine: Lack of drug interaction
82. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir (RTV) combinations in healthy volunteers
83. Effect of nelfinavir (NFV) on short and long term plasma exposure of saquinavir in hard gel capsule (SQV-HGC) during TID and BID dosing regimens
84. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
85. Combining ritonavir and indinavir decreases IDV associated nephrolithiasis
86. Intramural AIDS Program. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations
87. Pharmacokinetics of the triple combination of saquinavir, ritonavir, and efavirenz in HIV-positive patients
88. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir
89. Pharmacokinetic (PK) interaction between the HIV protease inhibitors tipranavir and ritonavir
90. Pharamcokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers
91. Delavirdine (D) and marketed protease inhibitors (PIs): Pharmacokinetic (PK) interaction studies in healthy volunteers
92. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction
93. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immuno deficiency virus
94. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium
95. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers
96. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M intracellulare infection
97. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients
98. Fluconazole and enhanced effect of rifabutin prophylaxis
99. Indinavir concentrations and St John's wort
100. St John's wort: Effect on CYP3A4 activity
101. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)
102. Constituents of garlic inhibit cytochrome P450 3A4 mediated drug metabolism
103. Alterations in hepatic phase I and phase II biotransformation enzymes by garlic oil in rats
104. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic
105. Regulation of hepatic cytochrome P-450 during infectious disease
106. Drug-cytokine interactions: Mechanisms and clinical implications
107. Interleukin-2 in the treatment of HIV disease
108. Interleukin-2: A review of its pharmacological properties and therapeutic use in patients with cancer
109. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus
110. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
111. Indinavir concentrations and antiviral effect
112. Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy
113. Therapeutic drug monitoring of antiretrovirals: Ready for the clinic?